Sanofi’s COVID-19 Vaccine Generates Strong Antibody Response in Animals, Human Trials to Begin in November

Sanofi’s (Paris, France) experimental COVID-19 vaccine developed jointly with Translate Bio (Lexington, MA, USA) generated high amounts of protective neutralizing antibodies in early-stage animal studies.

In its latest regulatory filing, Translate Bio has presented preclinical data on the messenger RNA vaccine which is similar to the mRNA technology adopted by Moderna Inc. for its COVID-19 vaccine and prompts the body to produce a key protein from the SARS-CoV-2 virus, thus inducing an immune response. In its regulatory filing Translate Bio, which has entered into a potential USD 2 billion deal with Sanofi for the development of the COVID-19 vaccine, cited Sanofi's presentation slides showing three doses of the vaccine candidate had induced neutralizing antibodies and T-cell responses in animal studies.


Translate Bio has stated in its filing that the data “demonstrate that two immunizations of the mRNA vaccine induced high neutralizing titers that are comparable to the upper range of those observed in infected humans.” According to Translate Bio, the experimental COVID-19 vaccine developed alongside Sanofi will now be tested on humans, starting in November.

Related Links:
Sanofi
Translate Bio